NCT04593641View on ClinicalTrials.gov

This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

October 26, 2020

Study Completion Date

April 5, 2021

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

CT-P59

administered

Trial Locations (1)

Unknown

Incheon Medical Center, Incheon

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04593641 - This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19) | Biotech Hunter | Biotech Hunter